FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL ReconstructionByVictoria JohnsonJanuary 15th 2026
FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia GravisByVictoria JohnsonJanuary 14th 2026
Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus ErythematosusByChelsie DermanJanuary 14th 2026
The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MDByRosalind Ramsey-Goldman, MDJanuary 13th 2026
Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease ControlByVictoria JohnsonJanuary 12th 2026